Microsaic Systems - Result of AGM
30/06/2022 12:11
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220630:nRSd8515Qa&default-theme=true
RNS Number : 8515Q Microsaic Systems plc 30 June 2022
30 June 2022
Microsaic Systems PLC
("Microsaic" or "the Company")
Result of Annual General Meeting
The Company is pleased to announce that at its Annual General Meeting held
earlier today, all five ordinary resolutions put to the meeting were duly
passed. The special resolution relating to the disapplication of pre-emption
rights did not achieve the required 75% of votes cast and therefore was not
passed.
The voting results of the AGM were as follows:
No. Resolution For* Against
1 To approve the annual report and accounts for the year ended 31 December 2021. 65.2% 34.8 %
2 To re-appoint and authorise the remuneration of the Company's auditor. 100.0% 0.0%
3 To re-elect Bob Moore Burton as a director. 99.8% 0.2%
4 To re-elect Dr Nigel Burton as a director. 65.2% 34.8%
5 To give the directors a general authority to allot shares in the Company and 99.4% 0.6%
to grant rights to subscribe for, or to convert any security into, shares in
the Company.
6 To empower the directors to allot equity securities for cash. 63.4% 36.6%
* Includes proxies received to be voted at the discretion of the Chairman.
Enquiries:
Microsaic Systems plc +44 (0)734 0055 648
Gerry Brandon Chairman
Singer Capital Markets +44 (0)20 7496 3000
(Nominated Adviser & Joint Broker)
Aubrey Powell / Tom Salvesen / George Tzimas
Turner Pope Investments (TPI) Limited (Broker) +44 (0) 20 3657 0050
Andy Thacker / James Pope
About Microsaic
Microsaic develops and commercialises micro-engineering chip-based mass
spectrometry equipment. Microsaic has a robust patent portfolio in
cutting-edge technology purpose built for "Industry 4.0" which enables
analytical detection and characterisation at the point-of-need, whether within
a human health environment, conventional laboratory setting, or within a
bioprocessing facility for continuous mass spectrometer detection and
monitoring of data at any step in the process workflow, or in frontline
environmental monitoring
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGFMMBTMTMJBLT